“…The 11 known β-thalassemia mutations including -29(A→G), -28 (A→G), CD17 (A→T), β E (CD26 G→A), IVS-1-1(G→T), IVS-1-5(G→C), CD27-28(+T), CD41-42 (-CTTT), CD43 (G→T), CD71-72(+A) and IVS-2- 654(C→T) [1], the two common deletions including Chinese G γ + ( A γδβ 0 ) thalassemia [22] and Southeast Asian hereditary persistence of fetal hemoglobin (SEA-HPFH) [23], the three common α-thalassemia deletions (-- SEA , -α 3.7 and -α 4.2 ) [1], the six non-deletional mutations (α cd30 ,α cd31 ,α cd59 ,α QS ,α CS , and α WS ) [1], the ααα anti-3.7 or ααα anti-4.2 triplication [24,25] and XmnI site -158 of the G γ-globin gene [26,27] were analyzed by previously described methods. Further sequence analysis was applied on both β 0 /β 0 and β + /β N or β 0 /β N samples, analyzed targets for the former (β 0 /β 0 ) include both 3'HS1 and 5'HS2 core region, the promoters of the G γ- and A γ-globin genes, the (AT)x(T)y sequence variations at the position -540 of the β-globin gene, a single-nucleotide polymorphism (SNP) of rs11886868 in the BCL11A gene, as well as the whole α2- and α1-globin genes; and those for the latter (β + /β N or β 0 /β N ) include the core regions of both 5'HS2 and 5'HS3, the whole β-globin gene and AHSP gene, and the full-lenghth cDNA of GATA-1 generated by RT-PCR from mRNA.…”